Issue 16, 2021

Targeted delivery of dexamethasone in acute pneumonia

Abstract

Pneumonia has contributed to significant mortality owing to the irreversible injury to the lungs and severe inflammation of the tissue. Dexamethasone (DEX) is regarded as an effective drug to relieve the level of pneumonia, while the adverse effect of which is non-negligible. Here, we developed a targeted delivery strategy based on platelet-derived extracellular vesicles (PEVs), which are naturally occurring nanoparticles released by platelets, for DEX delivery in acute pneumonia, aiming to reduce the side effects and improve the therapeutic efficacy. Our strategy may shed light on the problems in DEX-based acute pneumonia therapy clinically.

Graphical abstract: Targeted delivery of dexamethasone in acute pneumonia

Supplementary files

Article information

Article type
Paper
Submitted
12 Jun 2021
Accepted
16 Jun 2021
First published
09 Jul 2021

Biomater. Sci., 2021,9, 5569-5576

Targeted delivery of dexamethasone in acute pneumonia

Q. Ma, C. Yao, H. Shi, J. Xu, H. Dai, Z. Fei, Y. Wu, T. Lu and C. Wang, Biomater. Sci., 2021, 9, 5569 DOI: 10.1039/D1BM00924A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements